Trial Profile

Phase I Clinical Study to Evaluate the Safety and Tolerability of a Monovalent Influenza a (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) in Healthy Adults Aged 18 to 50 Years

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Influenza A virus H7N9 vaccine nanopatch Vaxxas (Primary) ; Influenza A virus H7N9 vaccine nanopatch Vaxxas
Indications Influenza A virus H7N9 subtype
Focus Adverse reactions
Sponsors Vaxxas

20 Mar 2025 Protocol was amended to remove Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Injection 7.5 mcg Influenza A (H7N9) Injection.
18 Feb 2025 According to a Vaxxas media release, the company has completed enrollment of participants. And, Initial results from the trial are expected in the first half of 2025.
18 Feb 2025 Status changed from recruiting to active, no longer recruiting, According to a Vaxxas media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com